Emisphere Technologies specializes in advanced drug delivery systems, focusing on enhancing the oral bioavailability of peptides, proteins, and large molecules. The company operates in the pharmaceutical and biotechnology sectors, partnering with other firms to license its proprietary drug delivery technology, including Eligen B12. Emisphere's core business model revolves around research and development, leveraging its extensive library of carriers to facilitate the absorption of drugs without altering their chemical form or biological integrity. This technology is particularly useful for drugs that are typically degraded by the digestive tract, such as protein and peptide drugs. By inhibiting acid and enzyme-mediated degradation, Emisphere's solutions allow these drugs to be absorbed effectively via the gastrointestinal epithelium. The company generates revenue through partnerships and licensing agreements, providing its technology to pharmaceutical companies looking to convert injectable therapeutics into oral formulations.

Keywords: drug delivery, oral bioavailability, peptides, proteins, biotechnology, pharmaceutical, Eligen B12, absorption, gastrointestinal, partnerships.